Ocular Therapeutix Inc OCUL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OCUL is a good fit for your portfolio.
News
-
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis
-
Thinking about buying stock in Meta Platforms, Ocular Therapeutix, Phathom Pharmaceuticals, Revelation Biosciences, or Sunworks?
-
Stocks to Watch: Adobe, Amtech Systems, Ocular Therapeutix
Trading Information
- Previous Close Price
- $5.87
- Day Range
- $6.03–6.40
- 52-Week Range
- $2.00–11.31
- Bid/Ask
- $6.07 / $6.32
- Market Cap
- $954.66 Mil
- Volume/Avg
- 4.6 Mil / 2.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.04
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 267
- Website
- https://www.ocutx.com
Comparables
Valuation
Metric
|
OCUL
|
PTGX
|
VRDN
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 7.78 | 4.47 | 3.53 |
Price/Sales | 9.04 | 24.68 | 2,194.98 |
Price/Cash Flow | — | — | — |
Price/Earnings
OCUL
PTGX
VRDN
Financial Strength
Metric
|
OCUL
|
PTGX
|
VRDN
|
---|---|---|---|
Quick Ratio | 6.36 | 16.54 | 17.93 |
Current Ratio | 6.66 | 16.71 | 18.26 |
Interest Coverage | −6.47 | — | −137.76 |
Quick Ratio
OCUL
PTGX
VRDN
Profitability
Metric
|
OCUL
|
PTGX
|
VRDN
|
---|---|---|---|
Return on Assets (Normalized) | −44.13% | −16.60% | −42.76% |
Return on Equity (Normalized) | −244.33% | −18.20% | −82.42% |
Return on Invested Capital (Normalized) | −63.64% | −23.45% | −50.70% |
Return on Assets
OCUL
PTGX
VRDN
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ylhgcwsq | Ztbc | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Brkmbhw | Tnsgl | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Myptrpbv | Yfbjt | $103.7 Bil | |
MRNA
| Moderna Inc | Sdtgrbbt | Stdnb | $47.9 Bil | |
ARGX
| argenx SE ADR | Lnrtlspg | Csvs | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Zvmdlrcr | Xpc | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jncfpjhkz | Zldjvs | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bvdnzdwq | Rtnqmh | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ftplbbyxxb | Cbnkw | $12.8 Bil | |
INCY
| Incyte Corp | Pgkgwql | Fdcqp | $12.1 Bil |